Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Criteria:~Inclusion Criteria:~* The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)~* Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.~* diagnosed with major or main portal vein invasion (Vp3 or Vp4)~* KPS≥70；~* with no previous treatment~* No Cirrhosis or cirrhotic status of Child-Pugh class A only~* Not amendable to surgical resection ,local ablative therapy and any other cured treatment.~* The following laboratory parameters:~  * Platelet count ≥ 75,000/µL~ * Hemoglobin ≥ 8.5 g/dL~ * Total bilirubin ≤ 30mmol/L~ * Serum albumin ≥ 30 g/L~ * ASL and AST ≤ 5 x upper limit of normal~ * Serum creatinine ≤ 1.5 x upper limit of normal~ * INR ≤ 1.5 or PT/APTT within normal limits~ * Absolute neutrophil count (ANC) \>1,500/mm3~* Ability to understand the protocol and to agree to and sign a written informed consent document~Exclusion Criteria:~* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy~* Known history of HIV~* History of organ allograft~* Known or suspected allergy to the investigational agents or any agent given in association with this trial.~* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~* Evidence of bleeding diathesis.~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.~* Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug~* Serious non-healing wound, ulcer, or bone fracture~* Known central nervous system tumors including metastatic brain disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib combined with HAIC (Type: EXPERIMENTAL): Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).